Anzeige
Mehr »
Login
Montag, 17.02.2025 Börsentäglich über 12.000 News von 687 internationalen Medien
1,5 Mio. Unzen indiziert, 5,2 Mio. Unzen geschätzt - und es wächst weiter: Die Goldaktie mit neuem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14SSK | ISIN: US5288723027 | Ticker-Symbol: LX31
Tradegate
17.02.25
08:00 Uhr
0,748 Euro
-0,006
-0,73 %
1-Jahres-Chart
LEXICON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LEXICON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7480,78516:58

Aktuelle News zur LEXICON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.01.Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC Wainwright10
LEXICON PHARMACEUTICALS Aktie jetzt für 0€ handeln
30.01.Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Hold Rating at Needham & Company LLC6
29.01.Lexicon Pharmaceuticals jumps amid takeover speculation10
29.01.Lexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC Wainwright5
29.01.Lexicon Pharmaceuticals' (LXRX) "Hold" Rating Reaffirmed at Needham & Company LLC12
29.01.Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)5
21.01.Lexicon Pharmaceuticals, Inc.: Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain18
04.01.Executive reshuffles: WELL, SLG and LXRX23
02.01.LEXICON PHARMACEUTICALS, INC. - 8-K, Current Report1
02.01.Lexicon Appoints Scott Coiante As CFO, SVP1
02.01.Lexicon Pharmaceuticals, Inc.: Lexicon Appoints Scott Coiante as Chief Financial Officer309THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer...
► Artikel lesen
23.12.24Analyst Expectations For Lexicon Pharmaceuticals' Future24
20.12.24FDA rejects Lexicon's Zynquista for diabetes, kidney disease13
20.12.24Lexicon Pharmaceuticals, Inc.: Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin)329THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration...
► Artikel lesen
09.12.24Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead26
03.12.24Aktie von Lexicon Pharmaceuticals erreicht 52-Wochen-Tief bei 0,73 US-Dollar10
26.11.24Lexicon Pharmaceuticals, Inc.: Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)199Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov....
► Artikel lesen
22.11.24After FDA setbacks, Lexicon slashes commercial operations in transition back to clinical-stage outfit6
22.11.24Lexicon to disband sales team, lay off 60% of staff1
22.11.24Lexicon falls on restructuring program2
Seite:  Weiter >>
92 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1